Log in

NASDAQ:RDUS - Radius Health Stock Price, Forecast & News

-1.26 (-8.74 %)
(As of 03/29/2020 04:00 PM ET)
Today's Range
Now: $13.16
50-Day Range
MA: $17.44
52-Week Range
Now: $13.16
Volume471,391 shs
Average Volume752,518 shs
Market Capitalization$608.26 million
P/E RatioN/A
Dividend YieldN/A
Radius Health, Inc., a biopharmaceutical company, develops and commercializes endocrine therapeutics in the areas of osteoporosis and oncology. The company markets TYMLOS for the treatment of postmenopausal women with osteoporosis. It is also developing abaloparatide transdermal patch, a short-wear-time patch formulation of abaloparatide to treat postmenopausal women with osteoporosis; RAD1901, a selective estrogen receptor down-regulator for the treatment of metastatic breast cancer; and RAD140, a non-steroidal selective androgen receptor modulator to treat breast cancer. The company has collaborations and license agreements with 3M Company; Ipsen Pharma SAS; Eisai Co. Ltd.; Duke University; and Teijin Limited. Radius Health, Inc. was founded in 2003 and is headquartered in Waltham, Massachusetts.
Read More
Radius Health logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:RDUS



Sales & Book Value

Annual Sales$173.32 million
Book Value($0.92) per share


Net Income$-132,990,000.00


Market Cap$608.26 million
Next Earnings Date5/13/2020 (Estimated)

Receive RDUS News and Ratings via Email

Sign-up to receive the latest news and ratings for RDUS and its competitors with MarketBeat's FREE daily newsletter.

Radius Health (NASDAQ:RDUS) Frequently Asked Questions

How has Radius Health's stock been impacted by COVID-19 (Coronavirus)?

Radius Health's stock was trading at $16.06 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, RDUS stock has decreased by 18.1% and is now trading at $13.16. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Radius Health?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Radius Health in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Radius Health.

When is Radius Health's next earnings date?

Radius Health is scheduled to release its next quarterly earnings announcement on Wednesday, May 13th 2020. View our earnings forecast for Radius Health.

How were Radius Health's earnings last quarter?

Radius Health Inc (NASDAQ:RDUS) posted its earnings results on Thursday, February, 27th. The biopharmaceutical company reported ($0.54) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.74) by $0.20. The biopharmaceutical company earned $55.67 million during the quarter, compared to analysts' expectations of $53.21 million. Radius Health had a negative return on equity of 929.94% and a negative net margin of 76.73%. View Radius Health's earnings history.

What guidance has Radius Health issued on next quarter's earnings?

Radius Health updated its FY 2020 Pre-Market earnings guidance on Thursday, February, 27th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $220-235 million, compared to the consensus revenue estimate of $246.17 million.

What price target have analysts set for RDUS?

7 equities research analysts have issued 1 year price objectives for Radius Health's stock. Their forecasts range from $27.00 to $40.00. On average, they expect Radius Health's stock price to reach $33.50 in the next twelve months. This suggests a possible upside of 154.6% from the stock's current price. View analysts' price targets for Radius Health.

What are Wall Street analysts saying about Radius Health stock?

Here are some recent quotes from research analysts about Radius Health stock:
  • 1. HC Wainwright analysts commented, "Our $26 price target is based on an 80% probability of success adjusted-DCF analysis including just Korsuva U.S. sales in CKD-aP, comprising peak IV Korsuva annual sales over $500M in the hemodialysis population, and $300M peak oral Korsuva sales in Stage 3-5 CKD (the latter even further risk-adjusted to <$100M in our model at 30% probability of success pre-Phase 2). Our DCF reflects a 10% WACC discount and 0% terminal growth beyond 2028. If our DCF valuation with IV Korsuva entirely de-risked (and oral still at 30%), all else equal, would yield a CKD-aP driven valuation of $35/share. That does not yet include any explicit value for Korsuva ex-U.S."" (5/9/2019)
  • 2. According to Zacks Investment Research, "Radius’ lead drug, Tymlos, continues to gain traction. In the first six weeks of 2019, the drug captured a 29% share of the U.S. anabolic osteoporosis market and more than 40% of new anabolic patient starts. Tymlos captured, on average, 20% of the U.S. anabolic osteoporosis market in 2018. In the fourth quarter, the drug’s average U.S. anabolic market share grew to 26% and achieved a 39% share of new anabolic patient starts. However, Radius suffered a setback when the European Commission refused to approve the drug. While the market for postmenopausal osteoporosis provides significant commercial potential, it is pretty crowded with the presence of drugs like Amgen’s Prolia and Lilly’s Forteo. Shares have underperformed the industry in the past twelve months." (5/6/2019)

Has Radius Health been receiving favorable news coverage?

Media coverage about RDUS stock has been trending extremely negative recently, according to InfoTrie Sentiment. The research firm identifies negative and positive press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Radius Health earned a news impact score of -4.0 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the near term. View the latest news aboutRadius Health.

Who are some of Radius Health's key competitors?

What other stocks do shareholders of Radius Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Radius Health investors own include Verizon Communications (VZ), HCA Healthcare (HCA), Ryder System (R), Pandora Media (P), NVIDIA (NVDA), Wells Fargo & Co (WFC), Alibaba Group (BABA), Tandem Diabetes Care (TNDM), Tesla (TSLA) and Ford Motor (F).

Who are Radius Health's key executives?

Radius Health's management team includes the following people:
  • Mr. Jesper Høiland, Pres, CEO & Director (Age 59)
  • Mr. Jose Carmona, CFO, Sr. VP & Treasurer (Age 47)
  • Mr. Brent Hatzis-Schoch Esq., J.D., Sr. VP, Gen. Counsel & Sec. (Age 54)
  • Mr. Brian Nicholas Harvey, Advisor (Age 58)
  • Dr. Stavros C. Manolagas, Co-Founder & Member of the Scientific Advisory Board

What is Radius Health's stock symbol?

Radius Health trades on the NASDAQ under the ticker symbol "RDUS."

Who are Radius Health's major shareholders?

Radius Health's stock is owned by a variety of institutional and retail investors. Top institutional investors include State Street Corp (5.12%), Artisan Partners Limited Partnership (2.59%), Emerald Advisers LLC (1.95%), Goldman Sachs Group Inc. (1.84%), FMR LLC (1.52%) and Geode Capital Management LLC (1.43%). Company insiders that own Radius Health stock include Anthony Rosenberg, Debasish Roychowdhury, Growth N V Biotech, Jessica Hopfield, Joseph Francis Kelly and Willard H Dere. View institutional ownership trends for Radius Health.

Which institutional investors are selling Radius Health stock?

RDUS stock was sold by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, PNC Financial Services Group Inc., FMR LLC, Chicago Equity Partners LLC, UBS Group AG, Citigroup Inc., Candriam Luxembourg S.C.A., and Cubist Systematic Strategies LLC. Company insiders that have sold Radius Health company stock in the last year include Anthony Rosenberg, Debasish Roychowdhury, and Willard H Dere. View insider buying and selling activity for Radius Health.

Which institutional investors are buying Radius Health stock?

RDUS stock was purchased by a variety of institutional investors in the last quarter, including State Street Corp, Norges Bank, Renaissance Technologies LLC, Artisan Partners Limited Partnership, Jacobs Levy Equity Management Inc., Goldman Sachs Group Inc., First Trust Advisors LP, and State of New Jersey Common Pension Fund D. Company insiders that have bought Radius Health stock in the last two years include Growth N V Biotech, Jessica Hopfield, and Joseph Francis Kelly. View insider buying and selling activity for Radius Health.

How do I buy shares of Radius Health?

Shares of RDUS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Radius Health's stock price today?

One share of RDUS stock can currently be purchased for approximately $13.16.

How big of a company is Radius Health?

Radius Health has a market capitalization of $608.26 million and generates $173.32 million in revenue each year. The biopharmaceutical company earns $-132,990,000.00 in net income (profit) each year or ($2.89) on an earnings per share basis. Radius Health employs 398 workers across the globe. View additional information about Radius Health.

What is Radius Health's official website?

The official website for Radius Health is http://www.radiuspharm.com/.

How can I contact Radius Health?

Radius Health's mailing address is 950 WINTER STREET, WALTHAM MA, 02451. The biopharmaceutical company can be reached via phone at 617-551-4000 or via email at [email protected]

MarketBeat Community Rating for Radius Health (NASDAQ RDUS)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  497 (Vote Outperform)
Underperform Votes:  387 (Vote Underperform)
Total Votes:  884
MarketBeat's community ratings are surveys of what our community members think about Radius Health and other stocks. Vote "Outperform" if you believe RDUS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RDUS will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel